Literature DB >> 20460825

Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.

Ken Ogasawara1, Tomohiro Terada, Toshiya Katsura, Etsuro Hatano, Iwao Ikai, Yoshio Yamaoka, Ken-ichi Inui.   

Abstract

Hepatic drug transporters are responsible for both hepatic uptake and the biliary excretion of drugs. Expression changes in hepatic drug transporter genes have been observed in various pathophysiological conditions. However, it has not been comprehensively investigated what factors substantially influence the mRNA levels of hepatic drug transporters. In this study, we quantified the mRNA expression of 17 drug transporters using noncancerous liver tissue samples and carried out stepwise multiple regression analysis to identify the factors affecting their expression from 18 clinical variables. For 17 drug transporters, the mRNA level of organic anion transporting polypeptide (OATP) 2B1 was highest, followed by that of organic cation transporter 1, organic anion transporter 2, OATP1B1, OATP1B3, multidrug resistance-associated protein (MRP) 6, and MRP3. Stepwise multiple regression analysis demonstrated MRP4 mRNA level to be predicted with the greatest accuracy among 17 drug transporters. Of clinical variables entered into the prediction model for MRP4, hepatitis C virus (HCV) infection and liver cirrhosis were crucial factors affecting MRP4 mRNA and protein levels. Furthermore, HCV-related cirrhosis influenced the mRNA levels of 8 drug transporters besides MRP4. These findings indicate that HCV-related cirrhosis is a crucial factor affecting the expression of hepatic drug transporters, especially MRP4.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460825     DOI: 10.2133/dmpk.25.190

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  19 in total

Review 1.  Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Gene D Morse
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

2.  Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression.

Authors:  Natsuko Tsuda; Osamu Matsui
Journal:  Eur Radiol       Date:  2011-08-11       Impact factor: 5.315

3.  Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics.

Authors:  Sarah Billington; Adrian S Ray; Laurent Salphati; Guangqing Xiao; Xiaoyan Chu; W Griffith Humphreys; Mingxiang Liao; Caroline A Lee; Anita Mathias; Cornelis E C A Hop; Christopher Rowbottom; Raymond Evers; Yurong Lai; Edward J Kelly; Bhagwat Prasad; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-11-14       Impact factor: 3.922

4.  Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.

Authors:  Sathej Gopalakrishnan; Sven Mensing; Rajeev M Menon; Jiuhong Zha
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

5.  Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Authors:  Sarah J Schrieber; Roy L Hawke; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Catherine M Meyers; Edward Doo; Michael W Fried
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

Review 6.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

Review 7.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

8.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

Review 9.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

10.  Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.

Authors:  Li Wang; Carol Collins; Edward J Kelly; Xiaoyan Chu; Adrian S Ray; Laurent Salphati; Guangqing Xiao; Caroline Lee; Yurong Lai; Mingxiang Liao; Anita Mathias; Raymond Evers; William Humphreys; Cornelis E C A Hop; Sean C Kumer; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2016-08-19       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.